Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
111.87M | 91.28M | 17.16M | 10.29M | 63.17M | 75.00M | Gross Profit |
110.68M | 88.88M | 14.78M | 7.95M | -35.32M | -5.03M | EBIT |
-100.29M | -114.95M | -164.41M | -115.15M | -56.81M | -23.88M | EBITDA |
-83.27M | -92.74M | -143.16M | -105.26M | -55.71M | -19.37M | Net Income Common Stockholders |
-140.62M | -145.23M | -163.62M | -128.72M | -57.19M | -19.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
339.94M | 385.37M | 390.90M | 441.24M | 548.10M | 393.65M | Total Assets |
422.05M | 483.83M | 452.39M | 610.38M | 643.07M | 416.55M | Total Debt |
15.57M | 16.04M | 17.81M | 19.45M | 20.95M | 342.00K | Net Debt |
-83.06M | -107.04M | -18.15M | -51.86M | -474.77M | -250.11M | Total Liabilities |
388.03M | 412.97M | 364.29M | 348.28M | 286.64M | 19.82M | Stockholders Equity |
34.02M | 70.87M | 88.10M | 262.10M | 356.43M | 396.73M |
Cash Flow | Free Cash Flow | ||||
-102.21M | -135.69M | -121.61M | -73.95M | -47.29M | -14.73M | Operating Cash Flow |
-101.84M | -135.34M | -120.80M | -73.59M | -45.92M | -14.16M | Investing Cash Flow |
41.63M | 95.40M | 144.75M | -394.85M | 38.84M | 94.47M | Financing Cash Flow |
105.16M | 127.05M | -59.30M | 44.02M | 252.30M | -879.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
68 Neutral | $767.67M | ― | -6.33% | ― | 23.92% | -27.69% | |
60 Neutral | $702.19M | ― | -343.83% | ― | 387.20% | 21.00% | |
59 Neutral | $741.46M | 53.85 | -4.52% | ― | 92.31% | 78.17% | |
55 Neutral | $754.78M | ― | -55.12% | ― | ― | -60.26% | |
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% | |
48 Neutral | $503.27M | ― | -43.77% | ― | 20.38% | -194.93% | |
46 Neutral | $376.78M | ― | -75.77% | ― | ― | -44.25% |
On June 17, 2025, AnaptysBio, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were adopted. These included the election of three Class II directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the approval of amendments to the company’s 2017 Equity Incentive Plan. The meeting also featured non-binding advisory votes on executive compensation and the frequency of future advisory votes concerning executive compensation. These decisions are expected to impact the company’s governance and operational strategies moving forward.
The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.
On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis. The trial demonstrated that rosnilimab achieved JAK-like efficacy with significant improvements in disease activity and remission rates, maintaining durable responses for at least two months off drug. The findings suggest rosnilimab’s potential for extended dosing intervals and its promising impact in the $20 billion U.S. RA market.
The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.